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Available online 19 April 2017Prevalence of Kaposi sarcoma-associated herpesvirus (KSHV/HHV-8) varies greatly in different populations. We
hypothesized that the actual prevalence of KSHV/HHV8 infection in humans is underestimated by the currently
available serological tests. We analyzed four independent patient cohorts with post-surgical or post-chemother-
apy sepsis, chronic lymphocytic leukemia and post-surgical patients with abdominal surgical interventions.
Levels of specific KSHV-encoded miRNAs were measured by reverse transcription-quantitative polymerase
chain reaction (RT-qPCR), and KSHV/HHV-8 IgG were measured by immunoassay. We also measured specific
miRNAs from Epstein Barr Virus (EBV), a virus closely related to KSHV/HHV-8, and determined the EBV serolog-
ical status by ELISA for Epstein-Barr nuclear antigen 1 (EBNA-1) IgG. Finally, we identified the viral miRNAs by in
situ hybridization (ISH) in bone marrow cells. In training/validation settings using independent multi-institu-
tional cohorts of 300 plasma samples, we identified in 78.50% of the samples detectable expression of at least
one of the three tested KSHV-miRNAs by RT-qPCR, while only 27.57% of samples were found to be seropositive
for KSHV/HHV-8 IgG (P b 0.001). The prevalence of KSHV infection based onmiRNAs qPCR is significantly higher
than the prevalence determined by seropositivity, and this ismore obvious for immuno-depressed patients. Plas-
ma viral miRNAs quantification proved that EBV infection is ubiquitous. Measurement of viral miRNAs by qPCR
has the potential to become the “gold” standard method to detect certain viral infections in clinical practice.l Therapeutics, TheUniversity o
mbe Blvd, Houston, TX 77030








Early detection of common (e.g., herpesvirus) and new emerging vi-
ruses (e.g., Zika virus) infections is extremely important for control of
disease transmission, prompt initiation of treatment and prevention of
infection-related complications. Human herpesvirus 8 (HHV-8; KSHV,f
–
censeKaposi sarcoma-associated herpesvirus) is a member of the gamma-
herpes virus family that evolved to maintain life-long latent infections
in the human host (Levy, 1997; Luppi and Torelli, 1996; Mesri et al.,
2010). KSHV is a causative factor for Kaposi sarcoma, primary effusion
lymphoma, and some subtypes of multicentric Castleman disease
(Ganem, 2010). Unlike the other members of the gamma-herpes virus
family, wide variation is seen in the seroprevalence of KSHV, which is
generally high in African and Mediterranean regions (20%–80%), and
low in non-endemic areas such as the United States andNorthern Europe
(1.5%–7%) (Rohner et al., 2014; Stiller et al., 2014). These geographical
variations in KSHV/HHV-8 seroprevalence and the incidence of classic(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ed outside endemic areas are in immunosuppressed patients (e.g., HIV-
infected patients, and post-transplant recipients) (Osmond et al., 2002).
In the last two decades, modern techniques (e.g., real-time PCR or RT-
qPCR, ELISA) have improved identification of viral infections. However,
there is no agreement on a standard assay to detect the presence of
KSHV infection and thus estimate its prevalence (Bhutani et al., 2015).
Although the current method of choice is to detect antibodies produced
in the patients after being infected by KSHV, the seroprevalence of
KSHV varies greatly geographically and the true prevalence of KSHV
infection may be underestimated (Mesri et al., 2010; Stiller et al., 2014).
MicroRNAs (miRNAs) are short non-coding RNAs (ncRNAs) that
post-transcriptionally regulate gene expression, thereby affecting mul-
tiple cellular processes, and miRNAs can serve as biomarkers for prog-
nosis of different diseases including malignancies (Ambros, 2003;
Calin et al., 2002; Calin et al., 2005; Fabbri et al., 2011). Previous studies
led to the discovery of virally encodedmiRNAs that play important roles
in regulating the latent-lytic switch of gamma-Herpesviruses infections
(Mesri et al., 2010; Zhu et al., 2013). Viral miRNAs can modulate both
viral and host cellular gene expression during infections without gener-
ating antigenic viral proteins that can be detected by the host immune
system (Skalsky and Cullen, 2010). Changes in cellular and viralmiRNAs
expression levels in the circulation (plasma or serum) showed specific
patterns in various diseases (e.g., malignancies, sepsis, atherosclerosis)
(Boss et al., 2011; Fabris and Calin, 2016; Ferrajoli et al., 2015; Giza et
al., 2016; Herman et al., 2015; Tudor et al., 2014; Zhang et al., 2012).
These miRNAs remain in circulation in a stable form, being highly resis-
tant to acute changes in pH, endogenous RNase activity, and variations
in temperature (Shah and Calin, 2013). Furthermore, several mature
miRNAs, derived from 12 precursor miRNAs in the latency locus of the
KSHV genome, play important roles in KSHV-induced cell transforma-
tion (Cai et al., 2005; Samols et al., 2005). Moreover, we previously re-
ported that higher plasma levels of KSHV miRNAs are associated with
a worse clinical outcome in patients with sepsis (Tudor et al., 2014).
We hypothesized that, since viral DNA/messenger RNA/proteins cannot
be detected in all infected individuals, detection of miRNAs encoded by
viruses may represent a more sensitive assay to determine the true
prevalence of certain viral infections, including latent KSHV infection.
Therefore, we compared the results of measurement of plasma miRNA
by RT-qPCR to serological testing for KSHV in four groups of Caucasian
patients from US and Romania to determine the relative effectiveness
of the two methods to measure and detect evidence of occult KSHV
infection.Fig. 1. Schematic representation of the set of patient plasma samples used for the present study.
of bone marrow samples, and the processing steps followed in the study. Ro: Fundeni Clinical
MDACC), United States.2. Methods
2.1. Patients and Samples
We used 300 plasma samples from a total of 214 Caucasian patients
from four independent patient cohorts whose characteristics have been
previously described (Ferrajoli et al., 2015; Ferrajoli et al., 2013; Tudor
et al., 2014) (Fig. 1 and Table S1).We initially used a training cohort con-
taining 33 patientswith sepsis fromFundeni Clinical Hospital (FCH), Bu-
charest, Romania as previously reported in Tudor et al. (2014). We used
a validation cohort containing 43 patients with sepsis from The Univer-
sity of TexasMDAnderson Cancer Center (UT-MDACC), Houston, Texas,
US (Tudor et al., 2014). Two additional independent patient cohorts
were used: 43 patients that underwent abdominal surgery (with col-
lected samples at three time points: one day before surgery, and after
surgery day 1 and day 7) from FCH (Tudor et al., 2014); and 95 patients
with chronic lymphocytic leukemia (CLL) from UT-MDACC as previous-
ly reported (Ferrajoli et al., 2013; Ferrajoli et al., 2015). A schematic rep-
resentation of themain plasma samples cohorts andworkflow is shown
in Fig. 1. Bonemorrow (BM) samples from 8 independent patients with
CLL from UT-MDACC were used for miRNA In Situ Hybridization (ISH;
SupplementaryMethods).We selected only Caucasian patients because
they have the lowest reported incidence of HHV-8 infection and also to
have a homogenous population for the study and exclude bias related to
race as a study variable. All clinical data and blood samples were
obtained from participants who had given written informed consent,
according to protocols approved by the FCH Ethics Committee and
UT-MDACC Institution Review Board. For all the patients the age,
gender, diagnosis, lymphocytes count, white blood cells (WBC) count,
absolute neutrophils count (ANC), platelet count (PLT) and survival
status were known and used for the study (Tables S1 and S2).
2.2. RNA Extraction and Expression Analyses
Total plasma RNAs extraction and normalization (by addition of
fixed amount of 10 fmol per 100 μl of plasma of each C. elegansmiRNAs
cel-miR-39-3p and cel-miR-54-3p), reverse transcription and expres-
sion analyses (KSHV-miR-K12-4-3p, KSHV-miR-K12-10b, KSHV-miR-
K12-12*, EBV-miR-BART4 and EBV-miR-BHRF1-1) were performed as
previously described (See Supplementary Tables S1 and S3) (Bustin et
al., 2009; Ferrajoli et al., 2015; Ferrajoli et al., 2013; Muller et al., 2014;
Schwarzenbach et al., 2015; Tudor et al., 2014). Briefly, total plasma
RNA was reverse transcribed and amplified using the TaqMan®Workflowof the plasma sample collection from four independent patient cohorts and a set
Hospital (FCH), Romania; US: The University of Texas MD Anderson Cancer Center (UT-
184 E. Fuentes-Mattei et al. / EBioMedicine 20 (2017) 182–192miRNA Reverse Kit (Applied Biosystems) with primers/probes specific
for each miRNA described above using SsoFast™ Probes SuperMix
(Bio-Rad Laboratories, Hercules, CA) as previously described (Bustin et
al., 2009; Tudor et al., 2014; Ferrajoli et al., 2015). Each amplification
was performed in triplicates, Ct values beyond the upper limit of the
measuring system were imputed as 40, and the expression levels were
considered to be positive for Ct values ≤ 35, according to the MIQE rec-
ommendations (Bustin et al., 2009). To confirm this threshold, we used
twomiRNAs from zebrafish (dre-miR-456 and dre-miR-458) that share
no homology to the human genome and also are never ingested in the
humans' food (Supplementary Table S4). Supplementary Table S1 con-
tains a summary of all raw profiling data obtained by reverse transcrip-
tion-quantitative polymerase chain reaction (RT-qPCR) and ELISA. In
order to identify the detection limits of the method, we selected a
mimic viral miRNA for each virus (KSHV-miR-K12-12* and EBV-miR-
BART4) and the cellular miRNA hsa-miR-16-5p to perform a RT-qPCR
based standard curve of known copy numbers (0, 100, 250, 500, 103,
104, 5 × 104, 105, 106, 109, 1012 copy numbers) to correlate the miRNA
copy numbers with corresponding Ct values (Supplementary Fig. S9).
Plasma total RNA samples from CD-1® IGS mice were used as negative
controls for the presence of the viralmiRNAs (Supplementary Table S5).
2.3. Enzyme-Linked Immuno-Sorbent Assay (ELISA)
KSHV/HHV8 IgG ELISA assay (Advanced Biotechnologies, Inc.,
Eldersburg, MD)was performed according tomanufacturer's instructions
to evaluate the KSHV/HHV-8 serological status. Epstein-Barr nuclear
antigen 1 (EBNA-1) IgG ELISA assay (Diamedix, ERBA Diagnostics, Inc.,
Miami FL) was performed according to manufacturer's instructions to
evaluate the EBV serological status as previously described (Ferrajoli et
al., 2015). For reproducibility testing, we measured in two independent
days 28 samples randomly selected (Fig. S1).
2.4. miRNA In Situ Hybridization (ISH)
miRNA-ISH for two KSHV/HHV8 miRNAs (KSHV-miR-K12-4-3p,
KSHV-miR-K12-10b) and one EBV miRNA (EBV-miR-BHRF1-1) were
performed in 8 BM biopsy specimens of patients with CLL as previously
described (Ferrajoli et al., 2015). Briefly, double digoxigenin-labeled
locked nucleic acid probes (LNA; Exiqon, Vedbaek, Denmark) antisense
to the above miRNAs (Fig. 5 and Supplementary Figs. S4 and S8) were
hybridized on tissue sections for 3 h at 55 °C. Detection was accom-
plished with anti-DIG alkaline phosphate Fab fragment followed by
nitro blue tetrazolium chloride/5-bromo-4-chloro-3-indolyl phosphate
(NBT/BCIP) color development (Ventana, Roche, Basel, CH). U6 probe
reactivity was used as positive control, and the scrambled-miRNA probe
(Exiqon Vedbaek, Denmark) was used as negative control for staining.
2.5. Statistical Analysis
Chi-square test or Fisher's exact test was used to assess the efficacy
of differentmeasurementmethods to determine viral infection in differ-
ent cohorts. To find the relationship between white blood cells (WBC),
lymphocytes (LYM) and other clinical parameters and plasma pres-
ence/absence of a viral miRNA we first employed a Shapiro-Wilk test
and verify that the data doesn't follow a normal distribution. According-
ly, we apply the nonparametric test Mann-Whitney-Wilcoxon to assess
the relationship between the presence or absence of viral miRNA and
WBC or LYM levels. The nonparametric Kruskal-Wallis test (together
with Dunn's post hoc test) was further applied to assess the degree of
association between WBC, LYM levels and presence of none, one, two
or three viral miRNAs detected. The Fisher's exact test, Shapiro-Wilk
test, Mann-Whitney-Wilcoxon nonparametric test, Kruskal-Wallis
test, and Dunn's post hoc test analyses were performed in R (version
3.0.1) (http://www.r-project.org/). Chi-square test, Pearson correlation
and Spearman correlation analyses were performed in GraphPad Prism(version 6.0h). Statistical significance was defined as a P value less 0.05
(P b 0.05).
3. Results
3.1. The Selection of KSHV miRNAs to Measure and the Samples Selection
We investigated the prevalence of KSHV/HHV-8 infection in 300
plasma samples from 214 Caucasian adults from Europe and US based
on RT-qPCR measurements of viral miRNAs that are non-orthologous
(without complete sequence match) with any human miRNA or any
human genome sequence or transcript (Fig. 1). We quantified three
miRNAs specific for KSHV viral infection latent phase (KSHV-miR-K12-
4-3p) and lytic phase (KSHV-miR-K12-10b and KSHV-miR-K12-12*),
respectively, selected according to a microarray screening of expressed
cellular and viral miRNAs in human mononuclear cells (Tudor et al.,
2014). In the same samples, we further compared the results obtained
with an assay commonly used in clinical practice, the KSHV/HHV-8
IgG measured by ELISA, as a measure for seropositivity (Goedert et al.,
1997; Spira et al., 2000).
We considered as “positive” the samples where the mean Ct values
of the duplicates was ≤35, which is in accordance to the MIQE recom-
mendations (Bustin et al., 2009). As we quantified miRNAs that are
not produced by the human genome and therefore should normally
not exist in human cells and body fluids, we further confirmed this
threshold by testing the levels of two additional non-human miRNAs
from zebrafish (dre-miR-456 and dre-miR-458). We selected this spe-
cie, as it is never used in the human diet; we obtained for dre-miR-
456 a mean Ct value of 38.77 (S.D. of ±1.31) while for dre-miR-458
wedidnot identified amplification till 40 cycles (Table S4). The 35 cycles
Ct threshold is therefore below two standard deviation (S.D.) of average
Ct value of themeanof triplicates for any of these two zebrafishmiRNAs
in any of the 5 human plasma samples tested for non-specific amplifica-
tion (Supplementary Table S4). To test the species-specificity for the de-
tection of viral infection, samples from CD-1® IGS mice were used as
negative controls for the presence of the viral miRNAs, as EBV and
KSHV infect humans, and not mice (Supplementary Table S5). Our re-
sults showed no amplification of the viral miRNAs in mouse samples,
except for ebv-miR-bart4, that has 100% similarity (with no gaps) for
18 nucleotides in miRNA sequence detected by the TaqMan specific
probe with the mouse Nef2 transcript variant 5. Thus, the ebv-miR-
bar4 results could be, therefore, considered as false-positive in the
mice samples (Supplementary Table S5). These data further support
the used threshold of ≤35 cycles. We used human hsa-miR-16, a well
expressed miRNA in plasma (Ferrajoli et al., 2013), as a control for
RNA quality, and selected only samples with mean Ct b 30 for this tran-
script for inclusion in this study. We further assessed the presence (Ct
≤ 35) or absence (Ct N 35) of KSHV miRNAs as binary result (Yes/No)
in a set of multi-institutional samples collected from patients from
two countries (US and Romania).
3.2. The Prevalence of KSHV Infection by Levels of Viral miRNAs is Signifi-
cantly Higher Than by KSHV IgG ELISA
In the training cohort of patients (n=33patientswith sepsis; Fig. 1)
we found that all patients had detectable expression of at least one
KSHV-miRNAs (27.27% with one, 39.39% with two and 33.33% with
three miRNAs detected), whereas only 36.36% of the patients were
found to be seropositive for KSHV/HHV-8 IgG (P b 0.001; Fig. 2A, Fig.
S2A, Table S6). As a reproducibility test for the ELISA assay,we randomly
selected a set of 28 samples and performed the assay in two indepen-
dent days and obtained highly significant positive correlations (Pearson
correlation of 0.952, P b 0.001 and a Spearman correlation of 0.861, P b
0.001) (Fig. S1). We then performed the same analyses in a validation
cohort (n=43patientswith sepsis, Fig. 1) andwe found similar results:
all patients had detectable expression of KSHV-miRNAs (27.91% with
Fig. 2. KSHVmiRNAs vs. KSHV/HHV-8 IgG as plasma biomarkers for KSHV infection. a. Percentage of patients positive (Ct value ≤ 35) for the plasma expression of one, two or three KSHV-
miRNAs (KSHV-miR-K12-4-3p, KSHV-miR-K12-10b and KSHV-miR-K12-12*) (upper panels). Percentage of patients positive for the plasma KSHV/HHV8 IgG (lower panels). P b 0.001 as
analyzedwith Chi-square test. See individual analysis of the patient cohorts in Table S6 and Table S7. b. Percentage of patients positive (Ct value ≤ 35) for the plasma expression of one, two
or three KSHV-miRNAs (KSHV-miR-K12-4-3p, KSHV-miR-K12-10b and KSHV-miR-K12-12*) and percentage of patients positive for the plasma KSHV/HHV8 IgG (left panel). Number of
patients (300 plasma samples of 214 patients from four independent cohorts, including 43 surgical patients with samples before surgery, day1 post-surgery and day7 post-surgery)
positive (Ct value ≤ 35) for each of the plasma KSHV-miRNAs (KSHV-miR-K12-4-3p, KSHV-miR-K12-10b and KSHV-miR-K12-12*) and HHV-8/HHV8 IgG right panel. See statistical
analysis details in Table S8. c. Detection of the plasma KSHV-miRNAs (KSHV-miR-K12-4-3p, KSHV-miR-K12-10b and KSHV-miR-K12-12*) and HHV-8/HHV8 IgG in 300 plasma
samples of 214 patients from four independent cohorts (including 43 surgical patients with samples before surgery, day1 post-surgery and day7 post-surgery). Red color = positive
for expression (Ct value ≤ 35), black color = negative for expression, and grey color = not determined. See statistical analysis details in Table S8.
185E. Fuentes-Mattei et al. / EBioMedicine 20 (2017) 182–192one, 51.16% with two and 20.93% with three miRNAs detected), while
only 16.28% of the patients were found to be seropositive for KSHV/
HHV-8 IgG (P b 0.001; Fig. 2A, Fig. S2A, Table S6). Among the individual
miRNAs, KSHV-miR-K12-10b was detected in all of patients from both
training and validation cohorts (P b 0.001; Table S7).We performed the same measurements in two other independent
cohorts, one composed of 43 patients that underwent abdominal
surgery for various malignant or non-malignant diseases (P b 0.001;
Fig. 2A, Fig. S2B, Table S6), and a second consisting of 95 patients with
CLL (P b 0.001; Fig. 2A, Fig. S2C, Table S6), also showing increased
186 E. Fuentes-Mattei et al. / EBioMedicine 20 (2017) 182–192KSHV prevalence by the detection of the viral miRNAs compared to
the measurements of seropositivity for KSHV/HHV-8 IgG. For the
surgical patients' cohort, we obtained sequential samples collected
one day before surgery, one day post-surgery and one week post-
surgery. In surgical cohort we observed detectable expression of at
least one KSHV miRNA in 53.48% of the patients (before surgery, P
b 0.001), 97.67% of the patients (day 1 post-surgery, P b 0.001) and
76.74% of the patients (day 7 post-surgery, P b 0.001). Only 16.28%
of these patients were seropositive for KSHV/HHV-8 IgG (Fig. 2A,
Fig. S2B, Table S6). In the independent cohort of CLL patients (Fig. 1),
we found that 52.63% of the patients had detectable expression of
KSHV-miRNAs (37.89% with one, 10.53% with two and 4.21% with
three miRNAs detected), while only 34.74% of the patients were found
to be seropositive for KSHV/HHV-8 IgG (P b 0.001; Fig. 2A, Fig. S2C,
Table S6).
Analysis of all 214 patients from the four independent cohorts
showed detectable expression of at least one KSHV-miRNA in 78.50%
of the patients (36.45% with one, 26.64% with two and 15.42% with
three miRNAs detected), while only 27.57% of the patients were found
to be seropositive for KSHV/HHV-8 IgG (P b 0.001; Fig. 2B, C, Fig. S3).
Analysis of individual KSHV-miRNAs showed that KSHV-miR-K12-10b
was most common, detected in 73.83% of the patients (P b 0.001;
Table S8).Fig. 3. KSHV-miRNAs prevalence correlated to white blood cells (WBC) and lymphocytes coun
miRNAs not detected (n = 76) versus patients with KSHV-miRNAs detected (n = 222) (P =
miRNAs not detected (n = 76) and in patients with one KSHV-miRNAs detected (n = 113),
0.026 as analyzed with Kruskal-Wallis test; right panel). Outliers in cyan color represent sam
represent samples with both KSHV-miRNAs and KSHV IgG detected. b. Lymphocytes count in
patients with KSHV-miRNAs detected (n = 222) (P b 0.001; left panel). Lymphocytes count in
patients with one KSHV-miRNAs detected (n = 113), two KSHV-miRNAs detected (n = 71),
test; right panel). Outliers in cyan color represent samples with KSHV-miRNAs detected, bu
miRNAs and KSHV IgG detected.3.3. The Presence of Plasma KSHV miRNAs Correlates with Low WBC and
Low Lymphocytes Counts
We further check for correlation between plasma KSHVmiRNAs and
clinical parameters to strength the translational significance of our find-
ings. The data revealed the presence of viral KSHV-miRNAs in the vast
majority of cases with abnormal low WBC count and low lymphocyte
count where the ELISA fails to identify the presence of IgG against the
KSHV (Fig. 3, Fig. S4, Tables 1 and 2). More precisely, the viral miRNAs
were detected in 19 cases out of the 21 cases with abnormal low WBC
count (WBC b 4000 cell/μl; 90.48%), and in 26 cases out of the 27
cases with abnormal low lymphocyte count (LYM b 1000 cell/μl;
92.59%). Compared to these results, the detection power of KSHV IgG
antigen by ELISA was significantly lower as it was found to be positive
in only 3 among the 21 cases with abnormal low WBC count (14.29%;
Fisher test P b 0.001; Table 1), and in only 5 among the 27 caseswith ab-
normal low lymphocytes count (18.52%; Fisher test P b 0.001; Table 2).
When analyzed the patientswith highWBCor high LYMdefined as over
the 75 percentile according to data in Fig. 3, we identified that the viral
miRNAswere detected in 39 cases out of the 74 caseswith either abnor-
mal high WBC count (WBC N 34,075 cell/μl; 52.70%) or with abnormal
high lymphocyte count (LYM N 25,422 cell/μl; 52.70%). Compared to
these results, the detection power of KSHV IgG antigen by ELISA wast. a. White blood cells (WBC) count in patients from all independent cohorts, with KSHV-
0.0045; left panel). WBC count in patients from all independent cohorts, with KSHV-
two KSHV-miRNAs detected (n = 71), and three KSHV-miRNAs detected (n = 38) (P =
ples with KSHV-miRNAs detected, but no KSHV IgG detected, while outliers in red color
patients from all independent cohorts, with KSHV-miRNAs not detected (n = 76) and in
patients from all independent cohorts, with KSHV-miRNAs not detected (n = 76) and in
and three KSHV-miRNAs detected (n = 38) (P b 0.001 as analyzed with Kruskal-Wallis
t no KSHV IgG detected, while outliers in red color represent samples with both KSHV-
Table 1
Correlation between KSHV-miRNAs, EBV-miRNAs and ELISA detection in patients with white blood cells (WBC) count b 4000 cell/μl.
Blue color = plasma samples in which only KSHV-miRNAs, but no KSHV IgG were detected; Red color = plasma samples in which both KSHV-
miRNAs andKSHV IgGweredetected; Black color=plasma samples inwhichnoneKSHV-miRNAs andKSHV IgGwere detected; Light orangeback-
ground = positive detection; and Light blue background= no detection.
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only 27 among the 74 cases with either high WBC or high lymphocyte
count (36.49%; Fisher test P = 0.069; Fig. 3 and Table S1). Of note,
only 25% of the patients with all 3-tested KSHV-miRNAs positive were
also positive by ELISA (9 out of 36 cases).
3.4. EBV miRNAs Detection Identifies Ubiquitous Expression
To test if the finding of significantly higher identification by RT-qPCR
is specific for the KSHV/HHV-8 or more general, we selected another
member of the gamma-herpesvirus family, the Epstein-Barr virus
(EBV) that is reported to infect humans more frequently than KSHV
(Young et al., 2016).We also performed RT-qPCR to detect the presence
of viral miRNAs (selected after an initial screen by small RNAs deep se-
quencing as previously described) (Ferrajoli et al., 2015), and compared
to EBV seropositivity (defined as detection of EBNA-1 IgG by ELISA) to
assess viral infection prevalence (Fig. 4A, Figs. S5 and S6, Tables S9–
S11). Analysis of all four independent cohorts together shows detect-
able expression of at least one EBV-miRNAs in 98.99% of the patients,
while 95.97% of the patients tested positive for EBNA-1 IgG (P = 0.04,
Fig. 4B, C). The data also revealed that significantly more cases with ab-
normal low lymphocyte count (LYM b 1000 cell/μl; 26 out of 27 cases,
92.59%; Fisher test P = 0.005) were positive for the viral EBV-miRNAs
compared to EBV IgG antigen positivity by ELISA (17 out of 27 cases,
62.96%; Table 2). When analyzed the patients with high WBC or high
LYM defined as over the 75 percentile, we identified that the viral
miRNAs were detected in 100% of the 74 cases with either leukopenia
or lymphocytopenia, compared to the detection power of EBV IgG anti-
gen by ELISA (66 out of 74 cases, 89.19%; Fisher test P = 0.006; Table
S1). Of note, 168 out of 178 cases (94.38%) with all 2-tested EBV-
miRNAs positive were also positive by ELISA.3.5. Multiple Validation Methods Confirmed the RT-qPCR Findings
As these data were obtained by using commercially designed and
tested assays of qRT-PCR, we then validated our finding by performing
In Situ Hybridization (ISH) with a double goal: first, to detect the
KSHV/HHV-8 or EBV viral miRNAs by an independent technique using
another source, the bone marrow specimens from CLL patients. ISH is
based on the detection of the viral miRNA sequences by complementar-
ity with a locked nucleic acid (LNA) probe (Ferrajoli et al., 2015;
Nishimura et al., 2013; Silahtaroglu et al., 2004). The second goal was
to identify the types of cells harboring the viral miRNAs, being known
that BM is a tissue composed by multiple categories of blood cells. Our
results showed detection of the viral miRNAs in all 8 BM specimens
available in both malignant B cells and megakaryocytes (Fig. 5, Figs. S4
and S7), further confirming the ubiquitous presence of KSHV and EBV
infections in humans lymphocytes and other types of cells from blood
or other tissues could harbor the KSHV.
In order to further validate our findings, we performed a double
blinded experiment using randomly selected samples from the patient
cohorts. The results validated the initial RT-qPCR assessment and
showed statistically significant correlations between the two indepen-
dent measurements by different scientists (Supplementary Fig. S8 and
Table S12). Despite the wide Ct value range (Ct of 36 to 40) defining
the absence of miRNA, we found for all of the miRNAs tested statistical
significant correlation between original RT-qPCR results and theblinded
experiments performed from the initial step of plasma RNA extraction
(Supplementary Fig. S8).
Moreover, the detection limit for the viral miRNAs was similar with
the one for the ubiquitous human miR-16: RT-qPCR of the standard
curve of known copy numbers (0, 100, 250, 500, 103, 104, 5 × 104, 105,
106, 109, 1012 copy number) of mimic viral miRNA for each virus
Table 2
Correlation between KSHV-miRNAs, EBV-miRNAs and ELISA detection in patients with lymphocytes (LYM) count b 1000 cell/μl.
Blue color=plasma samples inwhich only KSHV-miRNAs, but noKSHV IgGwere detected; Red color=plasma samples inwhichboth KSHV-
miRNAs and KSHV IgGwere detected; Black color=plasma samples inwhich none KSHV-miRNAs andKSHV IgGwere detected; Light orange
background = positive detection; and Light blue background = no detection.
188 E. Fuentes-Mattei et al. / EBioMedicine 20 (2017) 182–192(KSHV-miR-K12–12* and EBV-miR-BART4) showed that N1000 copies
of each viral miRNAs tested, as well as of hsa-miR-16, are necessary to
be detected by RT-qPCR at Ct values ≤35 (Supplementary Fig. S9).
4. Discussion
Our data prove that the prevalence of latent preexisting or newly
acquired viral infections with viruses such as KSHV/HHV8 is
underestimated by the prevalence of seropositivity. A limitation of the
serological detection is low sensitivity that can lead to false negative re-
sults (Frances et al., 2009; Schatz et al., 2001). The viral miRNAs selec-
tion in our study was not random, but instead based on the
expression identified by an array profiling followed by functional stud-
ies showing direct targeting of Toll-like receptors, that in turns mediate
the antiviral immune responses by recognizing virus infection (Tudor et
al., 2014). The KSHV miRNAs have no homology with the human ge-
nome, and therefore could not generate “false-positive” results from
non-specific annealing of the RT probes to the human genome tran-
scripts. Furthermore, each of the five tested viral miRNAs have specific
and unique sequences of six nucleotides at 3–prime of the molecule
that are used for assay selectivity for the TaqMan miRNA probes (see
Supplementary Table S3), and therefore the cross-amplification did
not occurs and their quantitative detection can reliably measure
KSHV/EBV infection prevalence. Furthermore, we identified the pres-
ence of viral miRNAs by two different types of techniques, the RT-qPCR and miRNA ISH, further reducing the possibility of false negative
results. Because miRNAs are stable molecules with a degradation half-
life longer than viral antigens, they can serve as useful biomarkers in
blood samples stored for a long time (Shah and Calin, 2013).
In our previous study on septic patient cohorts also used here,we re-
ported that the sepsis patients had high levels of two KSHV miRNAs
(KSHV-miR-K12-10b and KSHV-miR-K12–12*) compared with non-
sepsis controls and increases one day after open surgery (Tudor et al.,
2014). We further showed in another study, that in CLL patients EBV
miRNA BHRF1-1 expression levels were significantly higher in the plas-
ma of patients comparedwith healthy individuals and observed a corre-
lation between higher BHRF1-1 expression levels and shorter patients
survival (Ferrajoli et al., 2015). Patients under stress due to surgery
also showed increases in KSHV viral miRNAs and KSHVmRNAs expres-
sion levels (Ferrajoli et al., 2015; Tudor et al., 2014). Here our results
showed that surgery can uncover those patients presenting false
negative results by immune testing profiling, but positive to KSHV/
HHV8 infection as shown by the viral miRNAs detection (Fig. 2, Fig. S2,
Table S6 and Table S7). All these data support a potential important
role of thesemiRNAs in thepathogeny andpoor clinical outcomeof sepsis
and CLL.
EBV (HHV-4) infection is quite ubiquitous in all human populations
(Young et al., 2016). The viralmiRNA selection for detection in our study
was based on expression array profile combined with the identification
of targeting tumor suppressor TP53 (Ferrajoli et al., 2015). As
Fig. 4. EBV-miRNAs vs. EBNA-1 IgG immunoassay as plasma biomarkers for EBV infection. a. Percentage of patients positive (Ct value ≤ 35) for the plasma expression of one or two EBV-
miRNAs (EBV-miR-BART4 andEBV-miR-BHRF1-1) (upperpanel). Percentage of patients positive for theplasma EBNA-1 IgG (bottompanel). P b 0.001 as analyzedwith Chi-square test. See
individual analysis of the patient cohorts in Tables S9 and S10. b. Number of patients (out of 214 patients) positive (Ct value ≤ 35) for eachof theplasma EBV-miRNAs (EBV-miR-BART4 and
EBV-miR-BHRF1-1) and EBNA-1 IgG. See statistical analysis details in Table S11. c. Detection of the plasma EBV-miRNAs (EBV-miR-BART4 and EBV-miR-BHRF1-1) and EBNA-1 IgG in 214
patients (including 43 surgical patients day 1 post-surgery). Red color = positive for expression (Ct value ≤ 35), black color = negative for expression, and grey color = not determined.
See statistical analysis details in Table S11.
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termining the presence of EBV infection in immunocompromised states.
Of note, if the miRNA detection in multiple human populations bymul-
tiple groups in the next future will confirm that quite 100% of human
population is EBV-positive this will have a great significance, and conse-
quently the testing of EBV positivity will be performed only in instances
where the viral quantification is essential, such as cancer diagnosis and
prognosis. In contrast with EBV, KSHV seropositivity is much lower; we
showed that latent infection is highly prevalent and KSHV miRNAs can
bedetected almost ubiquitously after surgery or in the immunocompro-
mised state of sepsis, both of which are conditions that can reactivatelatent KSHV infection. Finally, here we identified KSHV infection preva-
lence via detection of KSHV-miRNAs by RT-qPCR in patients with leuko-
penia and patients with lymphocytopenia. Detection of KSHV-miRNAs
was statistically significant higher compared to the results via ELISA de-
tection of KSHV IgG in these patients. Therefore, our data suggest that
the prevalence of KSHV infection is grossly underestimated by immuno-
logical methods. Measurement of KSHV-miRNAs by RT-qPCR for KSHV/
HHV8 viremia detectionmay be an important tool for screening the do-
nated blood supply or transplanted organs to prevent the spread of
KSHV infection. Our group and other groups have shown that infection
withmembers of the gamma-herpes virus family represent a risk factor
Fig. 5. Detection of viral miRNAs by In Situ Hybridization in Bone Marrow Biopsies. In Situ Hybridization (ISH) for the KSHV-miR-K12-4-3p and KSHV-miR-K12-10b, and the EBV-miR-
BHRF1-1 were performed in bone marrow tissue samples. Red dashed lines show the nucleus boundaries, red arrows point to cytoplasmic localization of the miRNA in lymphocytes-
derived cells, and yellow arrows point to cytoplasmic localization of the miRNA in megakaryocytes. Images were taken at 1000× magnification and the scale bar = 10 μm.
190 E. Fuentes-Mattei et al. / EBioMedicine 20 (2017) 182–192for diseases (e.g., CLL, severe sepsis) and development of infection-
related complications. The screening of day 1 post-surgery patients for
plasma KSHV-miRNAs could be an application of our study – the identi-
fication of high levels of KSHV miRNAs will classify the patient for
potential prophylactic large spectrum antibiotic therapy to prevent
severe sepsis in case of infections with hospital bacteria.
We tested Caucasian patients in order to increase the statistical
power of the study by excluding race as a variable. Moreover, the Cauca-
sian population has a low reported incidence of HHV-8 infection poten-
tially due to underestimation of seropositivity prevalence with current
serological detection, which has low sensitivity that can lead to false
negative results. Larger prospective studies with thousands of patients
from multiple geographic regions and races are needed to fully assess
the advantage of usingmiRNART-qPCRwith orwithout ELISA for detec-
tion of KSHV infection. This method is suitable to the detection inhuman bodyfluids (andnot only plasma) of any virus codifyingmiRNAs
(29 viruses according tomiRBase at http://www.mirbase.org/). Identifi-
cation of viral exposure is currently important in the management of
patients receiving stem cell transplantation or other highly T-cell
immunosuppressive therapies. Clearly, current KSHV/HHV8 serology
methods are failing to detect the majority of KSHV latency. Measure-
ment of the viral miRNAs described here allows a direct assessment of
the levels of viral derived regulators of the patient's immune system
andmay present advantages over the current ELISAmethod. Circulating
cell-free nucleic acids in plasma has been previously shown many de-
cades ago (Kamm and Smith, 1972). Circulating miRNAs exhibit re-
markable stability in various types of body fluids (e.g., whole blood,
serum, plasma, urine, saliva) (Weber et al., 2010), being resistant to
plasma RNase activity, as well as to severe physicochemical conditions,
such as freeze-thawing and extreme pH (Chen et al., 2008). This can be
191E. Fuentes-Mattei et al. / EBioMedicine 20 (2017) 182–192explained by their encapsulation into vesicular bodies (e.g., exosomes,
microvesicles), or by their binding to RNA-binding proteins (e.g.,
nucleophosmin 1, HDL, AGO-2) (Arroyo et al., 2011; Vickers et al.,
2011; Wang et al., 2010). The reduction of the KSHVmiRNAs levels be-
tween Day-1 and Day-7 post-surgery can be potentially explained by
their translocation from plasma in cells that represent the “sanctuaries”
for persistence, such as bone marrow B cells (as we showed by ISH, see
Fig. 5 and Supplementary Figs. S4 and S7) or endothelial cells.Moreover,
the time/labor cost of this newmethod can represent about one third of
the cost of the current ELISA method for KSHV. Our findings set the
ground for the development of KSHV viral infection detection approach
by multiplex RT-qPCR detection method of multiple viral miRNAs. This
strategy to detect viral infection based on the measurement of viral
miRNAs has the potential to become a “gold” standard method in the
clinical practice to detect viremia or latency of viruses in the general
population and in individuals with immunocompromised states.Funding/Support
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